Trade ORIC Pharmaceuticals, Inc. - ORIC CFD
Add to favourite- Summary
- Historical Data
Spread | 0.07 | ||||||||
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024929% | ||||||||
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.002707% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 50.00% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
Prev. Close | 9.61 |
Open | 9.56 |
1-Year Change | 71.63% |
Day's Range | 9.05 - 9.56 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Oct 16, 2024 | 9.61 | 0.43 | 4.68% | 9.18 | 9.71 | 9.18 |
Oct 15, 2024 | 9.47 | 0.29 | 3.16% | 9.18 | 9.57 | 9.18 |
Oct 14, 2024 | 9.50 | 0.34 | 3.71% | 9.16 | 9.77 | 9.13 |
Oct 11, 2024 | 9.29 | 0.06 | 0.65% | 9.23 | 9.35 | 9.10 |
Oct 10, 2024 | 9.24 | 0.14 | 1.54% | 9.10 | 9.36 | 8.94 |
Oct 9, 2024 | 9.24 | -0.07 | -0.75% | 9.31 | 9.46 | 9.09 |
Oct 8, 2024 | 9.45 | -0.05 | -0.53% | 9.50 | 9.82 | 9.41 |
Oct 7, 2024 | 9.47 | -0.06 | -0.63% | 9.53 | 9.60 | 9.37 |
Oct 4, 2024 | 9.57 | 0.03 | 0.31% | 9.54 | 9.73 | 9.39 |
Oct 3, 2024 | 9.52 | 0.00 | 0.00% | 9.52 | 9.70 | 9.42 |
Oct 2, 2024 | 9.74 | 0.18 | 1.88% | 9.56 | 9.84 | 9.51 |
Oct 1, 2024 | 10.02 | -0.11 | -1.09% | 10.13 | 10.13 | 9.64 |
Sep 30, 2024 | 10.21 | -0.19 | -1.83% | 10.40 | 10.85 | 9.96 |
Sep 27, 2024 | 10.61 | 0.28 | 2.71% | 10.33 | 10.81 | 10.33 |
Sep 26, 2024 | 10.32 | 0.24 | 2.38% | 10.08 | 10.49 | 9.90 |
Sep 25, 2024 | 9.97 | -0.71 | -6.65% | 10.68 | 10.98 | 9.60 |
Sep 24, 2024 | 10.71 | -0.06 | -0.56% | 10.77 | 10.80 | 10.49 |
Sep 23, 2024 | 10.71 | -0.57 | -5.05% | 11.28 | 11.43 | 10.62 |
Sep 20, 2024 | 11.24 | 0.27 | 2.46% | 10.97 | 11.66 | 10.74 |
Sep 19, 2024 | 11.13 | 0.26 | 2.39% | 10.87 | 12.76 | 10.87 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
ORIC Pharmaceuticals, Inc. Company profile
About ORIC Pharmaceuticals Inc
ORIC Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by overcoming resistance in cancer. The Company is focused on developing a diverse pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its experience within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. Its product candidates include ORIC-101, ORIC-533, ORIC-944 and ORIC-114. The Company’s ORIC-101 is a potent and selective small-molecule antagonist of the glucocorticoid receptor (GR), which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors. The Company’s second product candidate, ORIC-533, is an orally bioavailable, small-molecule inhibitor of CD73, a key node in the adenosine pathway in resistance to chemotherapy-and immunotherapy-based treatment regimens. Its ORIC-944, is being developed for prostate cancer and breast cancer.
Financial summary
BRIEF: For the nine months ended 30 September 2021, ORIC Pharmaceuticals Inc revenues was not reported. Net loss increased 23% to $55.9M. Higher net loss reflects Research and development - Balancing val increase from $15.4M to $36.5M (expense), General and administrative - Balancing increase of 93% to $10.2M (expense), Stock-based Compensation in SGA increase from $1.9M to $5.8M (expense).
Industry: | Bio Therapeutic Drugs |
240 E. Grand Ave
2nd Floor
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US
News
US earnings seasons off to a solid start as focus shifts to tech giants
The US earnings season has started on a positive note, with major banks exceeding expectations and boosting market sentiment.Key themes for the sector include investments in artificial intelligence, capital expenditure returns, and consumer trends in advertising and e-commerce. The S&P 500 continues to climb, driven by strong earnings, resilient economic growth, and the potential for interest rate cuts. Keep an eye on significant support and resistance levels as the market tests new record highs.
14:31, 17 October 2024ECB Preview: cooling growth and inflation call for another rate cut
Markets are convinced the European Central Bank (ECB) will cut rates by 25 basis points again at Thursday’s meeting.
12:41, 16 October 2024Australian labour force data forecast to reveal stable jobs market
Australia's labour market remained stable in September 2024, with the unemployment rate forecast to hold at 4.2%, supported by a 25,200 person rise in employment. Despite the economy teetering on the edge of recession, strong hiring trends persist, challenging market economists' predictions.
07:41, 15 October 2024Applying fundamental and technical strategies to Gold Trading
Last week, we visualised the key potential drivers of gold in a chart focused on recent performance. Understanding the factors that can move gold prices is essential, but translating that knowledge into effective trading strategies is where the real potential can lie.
08:00, 14 October 2024S&P 500 expected to deliver modest earnings growth in Q3
Earnings growth across the S&P 500 is expected to be modest in Q3, with a projected 4.2% increase in EPS, down from 7.8% in the previous quarter. Information technology, health care, and communication services are poised to drive growth, particularly IT with a forecasted 15% year-over-year EPS increase.
12:40, 11 October 2024US Core CPI tipped to remain unchanged in September
US inflation expectations are steady, with core CPI projected to remain at 3.2% for September while headline inflation moderates to its lowest level since February 2021. Despite the US Federal Reserve delivering a 50 basis point interest rate cut in September, stronger-than-expected job market data has raised concerns about sustained economic demand and inflation pressures.
07:10, 9 October 2024RBNZ expected to deliver “jumbo” rate cut
The Reserve Bank of New Zealand is set to cut interest rates during its upcoming meeting, with expectations of either a 25 or 50 basis point reduction. This move follows a 25 basis point cut in August as the RBNZ responded to the country’s recessionary conditions and inflation concerns.
08:48, 8 October 2024People also watch
Still looking for a broker you can trust?
Join the 650,000+ traders worldwide that chose to trade with Capital.com